Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection

Rungsakulkij, Narongsak; Suragul, Wikran; Mingphruedhi, Somkit; Tangtawee, Pongsatorn; Muangkaew, Paramin; Aeesoa, Suraida

doi:10.1186/s13027-018-0192-7

Cited by 11 publications

(10 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the data shown in Table 1, 5 studies reported post‐treatment death rates in HCC patients with versus without APT 30–34 . These studies included 3281 patients, with 930 (29.9%) deaths.…”

Section: Resultsmentioning

confidence: 99%

“…| RESULTS3.1 | Search results and study characteristicsThe PRISMA flow diagram depicts the article selection process (Figure1). Briefly, among the 493 articles screened, 156 articles were assessed for eligibility with 20 studies, 15 on HCC incidence and five on mortality outcome following treatment, which were finally included in the meta-analysis [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. …”

mentioning

confidence: 99%

See 1 more Smart Citation

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Lai

Matthaeis

Finotti

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

Aim To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post‐treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51–0.79; p < 0.001) as well as of post‐treatment mortality (OR: 0.54; 95%CI = 0.35–0.83; p = 0.006). Conclusions Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Lai

Matthaeis

Finotti

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Indeed, independent prognostic factors vary significantly in identical disease and treatment settings at different hospitals. For example, numerous studies have reported that tumor size, which is commonly involved in staging systems for HCC, is not an independent prognostic factor for HCC after resection (16,17). Therefore, considering disparities in prognostic factors influenced by external factors, the performance of a model is likely to be most effective in the center from which the model was derived.…”

Section: Discussionmentioning

confidence: 99%

Probabilistic ratiocination of hepatocellular carcinoma after resection: evaluation of expected to be promising approaches

et al. 2021

View full text Add to dashboard Cite

Background: Precise prediction of survival after treatment is of great importance for patients with diseases with high mortality. RNA sequencing data and deep learning (DL) methods are expected to become promising approaches in the development of prediction models in the future. We aimed to evaluate the optimal covariates and methodology for patients with hepatocellular carcinoma (HCC) undergoing surgical resection. Methods: The Cox proportional hazards regression model and the DL approach were used to develop prediction models incorporating clinical, genetic, and combined clinical and genetic variables for survival prediction in patients with HCC after resection. A total of 1,114 patients and 184 patients were enrolled in the present study from 2,163 and 601 patients from Eastern Hepatobiliary Surgery Hospital and Renji Hospital, respectively. The models were internally validated through random sampling and externally validated in clinical cohorts. Between-model comparisons were carried out in terms of the integrated discrimination improvement and net reclassification index. Results: The Cox and DL clinical models were developed by adopting 7 independent prognostic factors (total bilirubin, prothrombin time, tumor size, tumor number, lymph node metastasis, and vascular invasion) and 22 clinical factors, respectively. Both the Cox clinical model and the DL clinical model showed excellent performances in the derivation [area under the curve (AUC): 0.75 vs. 0.77] and validation (AUC: 0.83 vs. 0.80) sets. The derived Cox genetic model with 6 significant prognostic genes was not as effective as the DL approach involving 686 genes. A combined clinical and genetic approach modified the performances of both the Cox and DL models. The integrated discrimination improvement and net reclassification index of the DL clinical model were generally better than those of the Cox clinical model. Conclusions: Our Cox clinical model sufficiently provided precise survival prediction in patients with HCC after resection. It may serve as an accurate and cost-effective tool for predicting survival in such patients.

show abstract

“…Overall, 5083 patients from the 11 retrospective cohort studies were included in this study (12)(13)(14)(15)(17)(18)(19)(20)(21)(22)(23). The level of evidence was 2a.…”

Section: Characteristics Of the Selected Articlesmentioning

confidence: 99%

“…( 14 ) and Rungsakulkij et al . ( 15 ), there are no obvious connections between patient outcomes and NLR or PLR levels.…”

Section: Introductionmentioning

confidence: 99%

Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective

Zheng¹,

Yue²,

Gou³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) infection represents the major etiology of hepatocellular carcinoma (HCC) and results in poor outcomes. Accumulating evidence suggests that composite immune cell-based biomarkers such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have prognostic value in postoperative HCC patients. However, due to the complexity, differential etiology, and the presence of variable confounding factors in different studies, the relationship between these markers with clinical outcomes in HBV-related posthepatectomy HCC is unclear from an immune perspective. Thus, this meta-analysis was conducted to determine NLR and PLR and assess their relation to overall survival (OS) and recurrence-free survival (RFS) in patients with post-hepatectomy HCC with HBV infection. Methods:The databases PubMed, Embase, Scopus, and Cochrane Library were searched using relevant keywords. We included studies which compared the outcomes of RFS and OS between different levels of NLR and PLR in HBV-related HCC patients who had undergone hepatectomy. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were considered as effective measures and were calculated by a pooled analysis. Evidence supporting the association of neutrophils, platelets, and lymphocytes with HBV infection, liver injury, and tumor progression in HCC was evaluated.Results: A total of 11 cohort studies with 5083 patients were included. Elevated NLR was significantly

show abstract

Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection

Cited by 11 publications

References 60 publications

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Probabilistic ratiocination of hepatocellular carcinoma after resection: evaluation of expected to be promising approaches

Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective

Contact Info

Product

Resources

About